Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Characteristics of patients with and without low ESMD among underweight, normal-weight, or overweight patients with COPD in the Kyoto–Himeji cohort

From: Antigravity muscle density on computed tomography and health-related independence in normal weight patients with chronic obstructive pulmonary disease

 

Underweight

Normal weight

Overweight

Low ESMD

Normal ESMD

Low ESMD

Normal ESMD

Low ESMD

Normal ESMD

n

10

12

40

81

30

26

Age, years

77.0 (9.9)

79.8 (5.3)

74.9 (8.0) **

70.4 (7.5)

74.3 (6.9) *

69.7 (8.8)

Sex, Female, n (%)

2 (20.0%)

2 (16.7%)

2 (5.0%)

5 (6.2%)

1 (3.3%)

1 (3.9%)

Height, cm

159.3 (8.5)

159.3 (8.1)

165.2 (7.3)

166.0 (6.4)

164.7 (7.5)

165.2 (6.0)

BMI, kg/m2

17.5 (0.7)

16.3 (1.7)

22.5 (1.7)

22.3 (1.9)

27.8 (2.6)

27.0 (1.3)

Current smoker, n (%)

5 (50.0%)

4 (33.3%)

9 (22.5%)

20 (24.7%)

6 (20.0%)

6 (23.1%)

Pack-years

55.7 (26.7)

55.6 (18.9)

58.0 (28.0)

59.5 (31.3)

70.5 (34.4)

55.5 (32.7)

Hypertension, n (%)

4 (40.0%)

3 (25.0%)

27 (67.5%)

42 (51.9%)

20 (66.7%)

16 (61.5%)

Diabetes, n (%)

0 (0.0%)

0 (0.0%)

4 (10.0%)

13 (16.1%)

0 (0.0%) **

7 (26.9%)

Heart disease, n (%)

1 (10.0%)

1 (9.1%)

7 (18.0%)

13 (16.5%)

7 (23.3%)

7 (26.9%)

mMRC ≥ 2, n (%)

3 (30.0%) *

10 (83.3%)

9 (22.5%)

14 (17.3%)

6 (20.0%)

6 (23.1%)

CAT ≥ 10, n (%)

9 (90.0%)

9 (75.0%)

22 (55.0%)

36 (44.4%)

14 (46.7%)

12 (46.2%)

Life space assessment < 60, n (%)

3 (30.0%)

6 (54.6%)

8 (20.0%)

9 (11.1%)

5 (16.7%)

1 (3.9%)

Exacerbation ≥ 2, %

0 (0.0%)

1 (8.3%)

3 (7.5%)

4 (4.9%)

0 (0.0%)

2 (7.7%)

Inhaled corticosteroid, %

3 (30.0%)

5 (41.7%)

18 (45.0%)

33 (40.7%)

17 (56.6%)

17 (65.4%)

FEV1%predicted, %

49.7 (19.5)

37.7 (5.1)

59.3 (20.2)

66.2 (23.8)

68.8 (17.6)

70.0 (21.0)

FVC %predicted, %

77.5 (22.0)

68.0 (21.4)

88.4 (22.6)

93.8 (21.7)

91.3 (18.5)

90.7 (21.0)

FEV1/FVC

0.48 (0.09)

0.42 (0.10)

0.52 (0.11)

0.53 (0.12)

0.57 (0.09)

0.59 (0.10)

LAV%, %

25.8 (14.6)

27.6 (12.9)

16.9 (11.6)

15.3 (12.0)

9.3 (9.2)

10.2 (11.7)

SAD%, %

31.2 (9.2)

40.1 (12.1)

32.6 (9.2) **

27.3 (10.9)

23.4 (12.0)

21.1 (11.4)

Wall area, mm2

29.1 (4.1) *

25.7 (2.6)

28.2 (5.1)

27.7 (4.2)

30.4 (4.7)

27.2 (6.1)

TAC

329.6 (70.7) **

251.6 (48.0)

298.1 (66.3)

313.7 (79.9)

315.2 (62.2)

306.2 (64.2)

  1. The data are expressed as the means (standard deviations, SDs) and %
  2. Heart disease is defined as the presence of chronic heart failure or ischemic heart disease
  3. BMI, body mass index; CAT, COPD assessment test; ESMD, erector spinae muscle density; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LAV, low attenuation volume; mMRC, modified medical research council; SAD, small airway dysfunction; TAC, total airway count. * indicates p < 0.05, ** indicates p < 0.01
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us